Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Date: July 13, 2016
Pages: 45
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MD015D75E0EEN
Leaflet:

Download PDF Leaflet

Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Momenta Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Momenta Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of Momenta Pharmaceuticals, Inc.
  • The report provides overview of Momenta Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Momenta Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Momenta Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Momenta Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Momenta Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Momenta Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Momenta Pharmaceuticals, Inc. Snapshot
Momenta Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Momenta Pharmaceuticals, Inc. - Research and Development Overview
Key Therapeutic Areas
Momenta Pharmaceuticals, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Momenta Pharmaceuticals, Inc. - Pipeline Products Glance
Momenta Pharmaceuticals, Inc. - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Momenta Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Momenta Pharmaceuticals, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Momenta Pharmaceuticals, Inc. - Drug Profiles
adalimumab biosimilar
Product Description
Mechanism of Action
R&D Progress
necuparanib
Product Description
Mechanism of Action
R&D Progress

M-281

Product Description
Mechanism of Action
R&D Progress
abatacept biosimilar
Product Description
Mechanism of Action
R&D Progress
Antibody for Autoimmune Disorders and Inflammation
Product Description
Mechanism of Action
R&D Progress

M-230

Product Description
Mechanism of Action
R&D Progress

M-615

Product Description
Mechanism of Action
R&D Progress

M-706

Product Description
Mechanism of Action
R&D Progress

M-710

Product Description
Mechanism of Action
R&D Progress

M-730

Product Description
Mechanism of Action
R&D Progress

M-740

Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Autoimmune Diseases
Product Description
Mechanism of Action
R&D Progress
Momenta Pharmaceuticals, Inc. - Pipeline Analysis
Momenta Pharmaceuticals, Inc. - Pipeline Products by Target
Momenta Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
Momenta Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates
Momenta Pharmaceuticals, Inc. - Dormant Projects
Momenta Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
bevacizumab biosimilar
Momenta Pharmaceuticals, Inc. - Company Statement
Momenta Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Momenta Pharmaceuticals, Inc., Key Information
Momenta Pharmaceuticals, Inc., Key Facts
Momenta Pharmaceuticals, Inc. - Pipeline by Indication, 2016
Momenta Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Momenta Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Momenta Pharmaceuticals, Inc. - Phase III, 2016
Momenta Pharmaceuticals, Inc. - Phase II, 2016
Momenta Pharmaceuticals, Inc. - Phase I, 2016
Momenta Pharmaceuticals, Inc. - Preclinical, 2016
Momenta Pharmaceuticals, Inc. - Discovery, 2016
Momenta Pharmaceuticals, Inc. - Pipeline by Target, 2016
Momenta Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
Momenta Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
Momenta Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
Momenta Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
Momenta Pharmaceuticals, Inc., Subsidiaries

LIST OF FIGURES

Momenta Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
Momenta Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Momenta Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Momenta Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
Momenta Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
Momenta Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
Momenta Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Skip to top


Ask Your Question

Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: